Keywords
Last Name
Institution

Robert Rosenson

TitlePROFESSOR
InstitutionMount Sinai
DepartmentCardiology
Address7405 5th Avenue
Brooklyn NY 11209
Phone718-439-5111

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rosenson RS, Underberg JA. Systematic review: Evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther. 2013 Oct; 27(5):465-79.
      View in: PubMed
    2. Rosenson RS, Brewer HB, Ansell B, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013 Sep 10; 128(11):1256-67.
      View in: PubMed
    3. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'Agostino RB, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013 Sep-Oct; 7(5):484-525.
      View in: PubMed
    4. Rosenson RS, Gotto AM. When clinical trials fail to address treatment gaps: the failure of niacin-laropiprant to reduce cardiovascular events. Curr Atheroscler Rep. 2013 Jun; 15(6):332.
      View in: PubMed
    5. Muntner P, Levitan EB, Brown TM, Sharma P, Zhao H, Bittner V, Glasser S, Kilgore M, Yun H, Woolley JM, Farkouh ME, Rosenson RS. Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010. Am J Cardiol. 2013 Sep 1; 112(5):664-70.
      View in: PubMed
    6. Berman JP, Farkouh ME, Rosenson RS. Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs. 2013 Jun; 18(2):193-205.
      View in: PubMed
    7. Medford RM, Dagi TF, Rosenson RS, Offermann MK. Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield. Curr Atheroscler Rep. 2013 May; 15(5):321.
      View in: PubMed
    8. Brown TM, Tanner RM, Carson AP, Yun H, Rosenson RS, Farkouh ME, Woolley JM, Thacker EL, Glasser SP, Safford MM, Muntner P. Awareness, treatment, and control of LDL cholesterol are lower among U.S. adults with undiagnosed diabetes versus diagnosed diabetes. Diabetes Care. 2013 Sep; 36(9):2734-40.
      View in: PubMed
    9. Lee SR, Jung JM, Jung LY, Lee JH, Lee SH, Rhee KS, Chae JK, Kim WH, Ko JK, Lee DH, Rosenson RS. Elevated coronary whole blood viscosity in acute coronary syndrome patients. Clin Hemorheol Microcirc. 2013 Jan 1; 55(1):85-94.
      View in: PubMed
    10. Goldberg RB, Rosenson RS, Hernandez-Triana E, Misir S, Jones MR. Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia. Diab Vasc Dis Res. 2013 May; 10(3):256-62.
      View in: PubMed
    11. Rosenson RS. Statin-induced lowering of LDL cholesterol associated with a reduced risk for cardiovascular events, not likely outweighed by the risk of diabetes, for people at low short-term risk of cardiovascular disease. Evid Based Med. 2013 Aug; 18(4):142-3.
      View in: PubMed
    12. Rosenson RS, Wright RS, Farkouh M, Plutzky J. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J. 2012 Nov; 164(5):672-80.
      View in: PubMed
    13. Cowan AQ, Cho DJ, Rosenson RS. Importance of blood rheology in the pathophysiology of atherothrombosis. Cardiovasc Drugs Ther. 2012 Aug; 26(4):339-48.
      View in: PubMed
    14. Davidson M, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Setze C, Carlson DM, Stolzenbach J. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
      View in: PubMed
    15. Rosenson RS, Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur Heart J. 2012 Dec; 33(23):2899-909.
      View in: PubMed
    16. Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res. 2012 Sep; 53(9):1767-82.
      View in: PubMed
    17. Rosenson RS. Clinical trials of HDL cholesterol-raising therapy: what have we learned about the HDL hypothesis from AIM-HIGH? Curr Atheroscler Rep. 2012 Jun; 14(3):190-2.
      View in: PubMed
    18. Goldberg RB, Rosenson RS, Hernandez-Triana E, Misir S, Jones MR. Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. J Clin Lipidol. 2012 Jul-Aug; 6(4):318-24.
      View in: PubMed
    19. Rosenson RS, Brewer HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012 Apr 17; 125(15):1905-19.
      View in: PubMed
    20. Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. J Clin Lipidol. 2012 Nov-Dec; 6(6):534-44.
      View in: PubMed
    21. Rosenson R, Horowitz J, Kaski JC, Krum H, Remme W. Clinical trials update Esc congress 2011. Cardiovasc Drugs Ther. 2012 Feb; 26(1):77-84.
      View in: PubMed
    22. Nicholls SJ, Cavender MA, Kastelein JJ, Schwartz G, Waters DD, Rosenson RS, Bash D, Hislop C. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc Drugs Ther. 2012 Feb; 26(1):71-5.
      View in: PubMed
    23. Rosenson RS, Fraser H, Goulder MA, Hislop C. Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome. Cardiovasc Drugs Ther. 2011 Dec; 25(6):539-44.
      View in: PubMed
    24. Sung KC, Rhee EJ, Kim H, Park JB, Kim YK, Rosenson RS. Prevalence of low LDL-cholesterol levels and elevated high-sensitivity C-reactive protein levels in apparently healthy Korean adults. Nutr Metab Cardiovasc Dis. 2012 Dec; 22(12):1061-6.
      View in: PubMed
    25. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, Bates ER, Bhatt DL, Bridges CR, Eisenberg MJ, Ferrari VA, Fisher JD, Gardner TJ, Gentile F, Gilson MF, Hlatky MA, Jacobs AK, Kaul S, Moliterno DJ, Mukherjee D, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352.
      View in: PubMed
    26. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis. 2011 Sep; 218(1):13-8.
      View in: PubMed
    27. Rosenson RS. Systemic inflammation and the dynamics of HDL cholesterol-associated residual cardiovascular risk. Curr Atheroscler Rep. 2011 Jun; 13(3):187-9.
      View in: PubMed
    28. Sung KC, Lim S, Rosenson RS. Hyperinsulinemia and homeostasis model assessment of insulin resistance as predictors of hypertension: a 5-year follow-up study of Korean sample. Am J Hypertens. 2011 Sep; 24(9):1041-5.
      View in: PubMed
    29. Vucic E, Rosenson RS. Recombinant high-density lipoprotein formulations. Curr Atheroscler Rep. 2011 Feb; 13(1):81-7.
      View in: PubMed
    30. Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams LA. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. Cardiovasc Drugs Ther. 2011 Feb; 25(1):47-57.
      View in: PubMed
    31. Horowitz JD, Rosenson RS, McMurray JJ, Marx N, Remme WJ. Clinical Trials Update AHA Congress 2010. Cardiovasc Drugs Ther. 2011 Feb; 25(1):69-76.
      View in: PubMed
    32. Rosenson RS, Brewer HB, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011 Mar; 57(3):392-410.
      View in: PubMed
    33. Rosenson RS. After FRANCIS: next steps in the clinical evaluation of varespladib methyl. Future Cardiol. 2011 Jan; 7(1):11-8.
      View in: PubMed
    34. Rosenson RS. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. Curr Opin Lipidol. 2010 Dec; 21(6):473-80.
      View in: PubMed
    35. Rosenson RS, Helenowski IB, Tangney CC. Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy. Cardiovasc Drugs Ther. 2010 Dec; 24(5-6):439-47.
      View in: PubMed
    36. Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS, Stolzenbach JC, Williams LA. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovasc Drugs Ther. 2010 Dec; 24(5-6):421-8.
      View in: PubMed
    37. Rosenson RS, Elliott M, Stasiv Y, Hislop C. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur Heart J. 2011 Apr; 32(8):999-1005.
      View in: PubMed
    38. Rosenson RS, Fraser H, Trias J, Hislop C. Varespladib methyl in cardiovascular disease. Expert Opin Investig Drugs. 2010 Oct; 19(10):1245-55.
      View in: PubMed
    39. Rubenfire M, Brook RD, Rosenson RS. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med. 2010 Oct; 123(10):892-8.
      View in: PubMed
    40. Rosenson RS. Physiochemically modified apolipoprotein B-containing lipoproteins and the risk of cardiovascular disease. J Intern Med. 2010 Oct; 268(4):316-9.
      View in: PubMed
    41. Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol. 2010 Sep 28; 56(14):1079-88.
      View in: PubMed
    42. Paras C, Hussain MM, Rosenson RS. Emerging drugs for hyperlipidemia. Expert Opin Emerg Drugs. 2010 Sep; 15(3):433-51.
      View in: PubMed
    43. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol. 2010 Jun 22; 55(25):2878-86.
      View in: PubMed
    44. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care. 2010 Jun; 33(6):1395-402.
      View in: PubMed
    45. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010 Jun 22; 121(24):2694-701.
      View in: PubMed
    46. Rosenson RS. New technologies personalize diagnostics and therapeutics. Curr Atheroscler Rep. 2010 May; 12(3):184-6.
      View in: PubMed
    47. Rosenson RS. Lp-PLA(2) and risk of atherosclerotic vascular disease. Lancet. 2010 May 1; 375(9725):1498-500.
      View in: PubMed
    48. Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis. 2010 Nov; 213(1):1-7.
      View in: PubMed
    49. Jeong SK, Cho YI, Duey M, Rosenson RS. Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment? Cardiovasc Drugs Ther. 2010 Apr; 24(2):151-60.
      View in: PubMed
    50. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010 May; 59(5):1153-60.
      View in: PubMed
    51. Rosenson RS. Functional assessment of HDL: Moving beyond static measures for risk assessment. Cardiovasc Drugs Ther. 2010 Feb; 24(1):71-5.
      View in: PubMed
    52. Bhavsar J, Rosenson RS. Adenosine transport, erythrocyte deformability and microvascular dysfunction: an unrecognized potential role for dipyridamole therapy. Clin Hemorheol Microcirc. 2010; 44(3):193-205.
      View in: PubMed
    53. Fioretto P, Dodson PM, Ziegler D, Rosenson RS. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol. 2010 Jan; 6(1):19-25.
      View in: PubMed
    54. Davidson MH, Rosenson RS. Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):52E-7E.
      View in: PubMed
    55. Rosenson RS, Gelb MH. Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Curr Cardiol Rep. 2009 Nov; 11(6):445-51.
      View in: PubMed
    56. Rosenson RS. Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production. Cardiovasc Drugs Ther. 2009 Aug; 23(4):289-94.
      View in: PubMed
    57. Rosenson RS. Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk. Cardiology. 2009; 114(3):212-25.
      View in: PubMed
    58. Rosenson RS. Management of non-high-density lipoprotein abnormalities. Atherosclerosis. 2009 Dec; 207(2):328-35.
      View in: PubMed
    59. Rosenson RS. A treasure of pharmacogenomic insights into postprandial lipoproteinemia and therapeutic responses to fibrate therapy: lessons from GOLDN. Curr Atheroscler Rep. 2009 May; 11(3):161-4.
      View in: PubMed
    60. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28; 53(17):1573-619.
      View in: PubMed
    61. Thande N, Rosenson RS. Vascular biomarkers in the metabolic syndrome. Expert Rev Mol Diagn. 2009 Apr; 9(3):209-15.
      View in: PubMed
    62. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009 Apr 28; 119(16):2250-94.
      View in: PubMed
    63. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care. 2009 Jun; 32(6):1087-91.
      View in: PubMed
    64. Rosenson RS, Hislop C, McConnell D, Elliott M, Stasiv Y, Wang N, Waters DD. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet. 2009 Feb 21; 373(9664):649-58.
      View in: PubMed
    65. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009 Feb 24; 119(7):931-9.
      View in: PubMed
    66. Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther. 2009 Feb; 23(1):93-101.
      View in: PubMed
    67. Alexander KP, Blazing MA, Rosenson RS, Hazard E, Aronow WS, Smith SC, Ohman EM. Management of hyperlipidemia in older adults. J Cardiovasc Pharmacol Ther. 2009 Mar; 14(1):49-58.
      View in: PubMed
    68. Rosenson RS, Pitt B. Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies. Nat Clin Pract Cardiovasc Med. 2009 Feb; 6(2):98-100.
      View in: PubMed
    69. Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring). 2009 Mar; 17(3):504-9.
      View in: PubMed
    70. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008 Nov 17; 102(10 Suppl):1K-34K.
      View in: PubMed
    71. Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther. 2008 Nov; 6(10):1319-30.
      View in: PubMed
    72. Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008 Nov; 5(4):319-35.
      View in: PubMed
    73. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008 Oct 28; 52(18):1502-17.
      View in: PubMed
    74. Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis. 2009 Jun; 204(2):342-4.
      View in: PubMed
    75. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2008 Nov; 103(11):2890-907.
      View in: PubMed
    76. Rosenson RS. Treatment with aspirin and dipyridamole is more effective than aspirin in reducing low shear blood viscosity. Microcirculation. 2008 Oct; 15(7):615-20.
      View in: PubMed
    77. Rosenson RS. Off-target toxicity: risks associated with adrenal corticoid activation in ILLUMINATE. Curr Atheroscler Rep. 2008 Jun; 10(3):227-9.
      View in: PubMed
    78. Rosenson RS. Biomarkers, atherosclerosis and cardiovascular events. Expert Rev Cardiovasc Ther. 2008 Jun; 6(5):619-22.
      View in: PubMed
    79. Morda JM, Ranella MJ, Rosenson RS. Role of statin therapy in stroke prevention. J Am Soc Hypertens. 2008 May-Jun; 2(3):131-9.
      View in: PubMed
    80. Rosenson RS, Huskin AL, Wolff DA, Helenowski IB, Rademaker AW. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis. 2008 Jun; 198(2):381-8.
      View in: PubMed
    81. Rosenson RS. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J. 2008 Mar; 155(3):499.e9-16.
      View in: PubMed
    82. Rosenson RS, Vracar-Grabar M, Helenowski I. Lipoprotein associated phospholipase A2 inhibition reduces generation of oxidized fatty acids: Lp-LPA2 reduces oxidized fatty acids. Cardiovasc Drugs Ther. 2008 Feb; 22(1):55-8.
      View in: PubMed
    83. Rosenson RS. SPARCL: statin therapy for stroke patients is not crystal clear. Curr Atheroscler Rep. 2007 Sep; 9(3):213-5.
      View in: PubMed
    84. Koh KK, Quon MJ, Rosenson RS, Chung WJ, Han SH. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int J Cardiol. 2008 Feb 29; 124(2):149-59.
      View in: PubMed
    85. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007 Aug; 30(8):1945-51.
      View in: PubMed
    86. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis. 2007 May; 7(5):358-68.
      View in: PubMed
    87. Rosenson RS. Measure for measure--sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy. Nat Clin Pract Endocrinol Metab. 2007 Feb; 3(2):72-3.
      View in: PubMed
    88. Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, Miller P, Palmer M, Sosef F. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis. 2007 Oct; 194(2):e154-64.
      View in: PubMed
    89. Davidson JA, Moreno PR, Badimon JJ, Lopez-Candales A, Maisonet Giachello AL, Ovalle F, Rodriguez CJ, Rosenson RS, Rodbard HW, Kannel WB. Cardiovascular disease prevention and care in Latino and Hispanic subjects. Endocr Pract. 2007 Jan-Feb; 13(1):77-85.
      View in: PubMed
    90. Davidson JA, Kannel WB, Lopez-Candales A, Morales L, Moreno PR, Ovalle F, Rodriguez CJ, Rodbard HW, Rosenson RS, Stern M. Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action. J Cardiometab Syndr. 2007; 2(4):238-43.
      View in: PubMed
    91. Davidson JA, Kannel WB, Lopez-Candales A, Morales L, Moreno PR, Ovalle F, Rodriguez CJ, Rodbard HW, Rosenson RS, Stern M. Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action. Ethn Dis. 2007; 17(3):568-73.
      View in: PubMed
    92. Rosenson RS. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus. Am J Cardiol. 2007 Feb 19; 99(4A):96B-104B.
      View in: PubMed
    93. Rosenson RS, Tangney CC. Preanalytical sources of measurement error: the conundrum of the homocysteine hypothesis. Atherosclerosis. 2007 Oct; 194(2):520.
      View in: PubMed
    94. Bays H, Blonde L, Rosenson R. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther. 2006 Nov; 4(6):871-95.
      View in: PubMed
    95. Rosenson RS. Field of confusion: future prospects for fibrate therapy in cardiovascular disease. Curr Atheroscler Rep. 2006 May; 8(3):219-22.
      View in: PubMed
    96. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis? Lancet Infect Dis. 2006 Apr; 6(4):242-8.
      View in: PubMed
    97. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006 Mar; 259(3):247-58.
      View in: PubMed
    98. Rosenson RS. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J. 2006 Mar; 151(3):556-63.
      View in: PubMed
    99. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol. 2006 Apr 17; 97(8A):69C-76C.
      View in: PubMed
    100. Rosenson RS. Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med. 2005 Oct; 118(10):1067-77.
      View in: PubMed
    101. Rosenson RS. Assessing risk across the spectrum of patients with the metabolic syndrome. Am J Cardiol. 2005 Aug 22; 96(4A):8E-10E.
      View in: PubMed
    102. Rosenson RS, Tangney CC, Langman CB, Parker TS, Levine DM, Gordon BR. Short-term reduction in bone markers with high-dose simvastatin. Osteoporos Int. 2005 Oct; 16(10):1272-6.
      View in: PubMed
    103. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis. 2006 Apr; 185(2):327-30.
      View in: PubMed
    104. Rosenson RS. Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. Curr Opin Cardiol. 2005 Jul; 20(4):313-7.
      View in: PubMed
    105. Rosenson RS. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. Curr Probl Cardiol. 2005 May; 30(5):241-79.
      View in: PubMed
    106. Betteridge DJ, Rosenson RS. Targeting dyslipidemia--the key to CHD risk reduction in the diabetic population? Diabetes Res Clin Pract. 2005 Jun; 68 Suppl 2:S1-2.
      View in: PubMed
    107. Rosenson RS. HDL-C and the diabetic patient: target for therapeutic intervention? Diabetes Res Clin Pract. 2005 Jun; 68 Suppl 2:S36-42.
      View in: PubMed
    108. Rosenson RS. Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets. Postgrad Med. 2005 Apr; 117(4):17-20, 23-7.
      View in: PubMed
    109. Rosenson RS, Tangney CC, Levine DM, Parker TS, Gordon BR. Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects. J Lab Clin Med. 2005 Feb; 145(2):83-7.
      View in: PubMed
    110. Rosenson R, Lloyd-Jones D. Critical appraisal of revised cholesterol guidelines for the very high-risk patient. Expert Rev Cardiovasc Ther. 2005 Jan; 3(1):173-8.
      View in: PubMed
    111. Smith SC, Anderson JL, Cannon RO, Fadl YY, Koenig W, Libby P, Lipshultz SE, Mensah GA, Ridker PM, Rosenson R. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the clinical practice discussion group. Circulation. 2004 Dec 21; 110(25):e550-3.
      View in: PubMed
    112. Rosenson RS. Statins: can the new generation make an impression? Expert Opin Emerg Drugs. 2004 Nov; 9(2):269-79.
      View in: PubMed
    113. Rosenson RS, Tangney CC, Levine DM, Parker TS, Gordon BR. Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia. Atherosclerosis. 2004 Nov; 177(1):77-81.
      View in: PubMed
    114. Rosenson RS, Reasner CA. Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Curr Opin Cardiol. 2004 Sep; 19(5):480-7.
      View in: PubMed
    115. Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther. 2004 Sep; 26(9):1400-10.
      View in: PubMed
    116. Rosenson RS, Wolff D. Comparison of two whole blood viscometers: implications for cardiovascular and thrombosis research. Thromb Haemost. 2004 Jul; 92(1):225-6.
      View in: PubMed
    117. Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am. 2004 Jun; 33(2):431-53, table of contents.
      View in: PubMed
    118. Smith SC, Milani RV, Arnett DK, Crouse JR, McDermott MM, Ridker PM, Rosenson RS, Taubert KA, Wilson PW. Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation. 2004 Jun 1; 109(21):2613-6.
      View in: PubMed
    119. Kumar A, Anel R, Bunnell E, Habet K, Neumann A, Wolff D, Rosenson R, Cheang M, Parrillo JE. Effect of large volume infusion on left ventricular volumes, performance and contractility parameters in normal volunteers. Intensive Care Med. 2004 Jul; 30(7):1361-9.
      View in: PubMed
    120. Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004 Mar 15; 116(6):408-16.
      View in: PubMed
    121. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 2004 Mar; 173(1):1-12.
      View in: PubMed
    122. Rosenson RS, Wolff D, Green D, Boss AH, Kensey KR. Aspirin. Aspirin does not alter native blood viscosity. J Thromb Haemost. 2004 Feb; 2(2):340-1.
      View in: PubMed
    123. Rosenson RS, Wolff D, Tangney CC. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia. Clin Sci (Lond). 2004 Feb; 106(2):215-7.
      View in: PubMed
    124. Wang S, Kensey K, Rosenson R. Interindividual variability of whole blood viscosity improved with standardized hydration. Clin Chim Acta. 2003 Nov; 337(1-2):181-2.
      View in: PubMed
    125. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther. 2003 Nov; 1(4):495-505.
      View in: PubMed
    126. Rosenson RS. Statin therapy: new therapy for cardiac microvascular dysfunction. Eur Heart J. 2003 Nov; 24(22):1993-4.
      View in: PubMed
    127. Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis. 2003 Nov; 171(1):87-96.
      View in: PubMed
    128. Rosenson RS, Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol. 2003 Jul 3; 92(1A):10i-8i.
      View in: PubMed
    129. Rosenson RS. Modulating atherosclerosis through inhibition or blockade of angiotensin. Clin Cardiol. 2003 Jul; 26(7):305-11.
      View in: PubMed
    130. Wang S, Boss AH, Kensey KR, Rosenson RS. Variations of whole blood viscosity using Rheolog-a new scanning capillary viscometer. Clin Chim Acta. 2003 Jun; 332(1-2):79-82.
      View in: PubMed
    131. Rosenson RS, Bays HE. Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day. Am J Cardiol. 2003 Apr 1; 91(7):878-81.
      View in: PubMed
    132. Vlastos GA, Tangney CC, Rosenson RS. Effects of hydration on blood rheology. Clin Hemorheol Microcirc. 2003; 28(1):41-9.
      View in: PubMed
    133. Rosenson RS, Brown AS. Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence. Curr Opin Lipidol. 2002 Dec; 13(6):625-30.
      View in: PubMed
    134. Rosenson RS. The rationale for combination therapy. Am J Cardiol. 2002 Nov 20; 90(10B):2K-7K.
      View in: PubMed
    135. Koenig W, Rosenson RS. Acute-phase reactants and coronary heart disease. Semin Vasc Med. 2002 Nov; 2(4):417-28.
      View in: PubMed
    136. Sher TG, Bellg AJ, Braun L, Domas A, Rosenson R, Canar WJ. Partners for Life: a theoretical approach to developing an intervention for cardiac risk reduction. Health Educ Res. 2002 Oct; 17(5):597-605.
      View in: PubMed
    137. Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. Clin Endocrinol (Oxf). 2002 Aug; 57(2):209-14.
      View in: PubMed
    138. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002 Jul 22; 162(14):1568-76.
      View in: PubMed
    139. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. 2002 Jul 15; 90(2):89-94.
      View in: PubMed
    140. Kennedy HL, Rosenson RS. Physicians' interpretation of "class effects": a need for thoughtful re-evaluation. J Am Coll Cardiol. 2002 Jul 3; 40(1):19-26.
      View in: PubMed
    141. Rosenson RS, Koenig W. High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. Curr Opin Cardiol. 2002 Jul; 17(4):325-31.
      View in: PubMed
    142. Rosenson RS. Statins and the risk of rhabdomyolysis. J Endocrinol Invest. 2002 Jul-Aug; 25(7):577.
      View in: PubMed
    143. Bostom AD, Brown RS, Chavers BM, Coffman TM, Cosio FG, Culver K, Curtis JJ, Danovitch GM, Everson GT, First MR, Garvey C, Grimm R, Hertz MI, Hricik DE, Hunsicker LG, Ibrahim H, Kasiske BL, Kennedy M, Klag M, Knatterud ME, Kobashigawa J, Lake JR, Light JA, Matas AJ, McDiarmid SV, Miller LW, Payne WD, Rosenson R, Sutherland DE, Tejani A, Textor S, Valantine HA, Wiesner RH. Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group. Am J Transplant. 2002 Jul; 2(6):491-500.
      View in: PubMed
    144. Rosenson RS, Shott S, Tangney CC. Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. Atherosclerosis. 2002 Apr; 161(2):433-9.
      View in: PubMed
    145. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis. 2002 Jan; 160(1):41-8.
      View in: PubMed
    146. Braun LT, Rosenson RS. Asessing coronary heart disease risk and managing lipids. Nurse Pract. 2001 Dec; 26(12):30-2, 34, 37-41; quiz 42-3.
      View in: PubMed
    147. Rosenson RS, Mosca L, Staffileno BA, Tangney CC. Variability in fibrinogen measurements: an obstacle to cardiovascular risk stratification. Atherosclerosis. 2001 Nov; 159(1):225-30.
      View in: PubMed
    148. Almeda FQ, Adler S, Rosenson RS. Metastatic tumor infiltration of the pericardium masquerading as pericardial tamponade. Am J Med. 2001 Oct 15; 111(6):504-5.
      View in: PubMed
    149. Staffileno BA, Braun LT, Rosenson RS. The accumulative effects of physical activity in hypertensive post-menopausal women. J Cardiovasc Risk. 2001 Oct; 8(5):283-90.
      View in: PubMed
    150. Rosenson RS, Shott S, Katz R. Elevated blood viscosity in systemic lupus erythematosus. Semin Arthritis Rheum. 2001 Aug; 31(1):52-7.
      View in: PubMed
    151. Rosenson RS, Shott S, Lu L, Tangney CC. Hypertriglyceridemia and other factors associated with plasma viscosity. Am J Med. 2001 Apr 15; 110(6):488-92.
      View in: PubMed
    152. Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis. 2001 Apr; 155(2):463-6.
      View in: PubMed
    153. Tangney CC, Mosca LJ, Otvos JD, Rosenson RS. Oral 17beta-estradiol and medroxyprogesterone acetate therapy in postmenopausal women increases HDL particle size. Atherosclerosis. 2001 Apr; 155(2):425-30.
      View in: PubMed
    154. Rosenson RS. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs. 2001; 1(6):411-20.
      View in: PubMed
    155. Rosenson RS. Basic mechanisms of stroke prevention with lipid-lowering therapy. Curr Atheroscler Rep. 2000 Mar; 2(2):120-5.
      View in: PubMed
    156. Rosenson RS. Biological basis for statin therapy in stroke prevention. Curr Opin Neurol. 2000 Feb; 13(1):57-62.
      View in: PubMed
    157. Rosenson RS. Hypertriglyceridemia and coronaryheart disease risk. Cardiol Rev. 1999 Nov-Dec; 7(6):342-8.
      View in: PubMed
    158. Stamos TD, Rosenson RS. Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis. 1999 Sep; 146(1):161-5.
      View in: PubMed
    159. Rosenson RS. Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep. 1999 Sep; 1(3):225-32.
      View in: PubMed
    160. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999 Mar 20; 353(9157):983-4.
      View in: PubMed
    161. Iliadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol. 1999 Jan; 22(1):25-8.
      View in: PubMed
    162. Rosenson RS, Tangney CC, Mosca LJ. Hormone replacement therapy improves cardiovascular risk by lowering plasma viscosity in postmenopausal women. Arterioscler Thromb Vasc Biol. 1998 Dec; 18(12):1902-5.
      View in: PubMed
    163. Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis. 1998 Oct; 140(2):271-80.
      View in: PubMed
    164. Bagdade JD, Liu XQ, Buchanan WF, Hafner J, Rosenson R. Accelerated cholesteryl ester transfer in patients with essential hypertension and the effect of ramipril treatment. Atherosclerosis. 1998 Sep; 140(1):167-72.
      View in: PubMed
    165. Rosenson RS, Tangney CC. Effects of tourniquet application on plasma viscosity measurements. Clin Hemorheol Microcirc. 1998 Jul; 18(2-3):191-4.
      View in: PubMed
    166. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998 May 27; 279(20):1643-50.
      View in: PubMed
    167. Rosenson RS, Tangney C. Intraindividual variability in plasma viscosity measurements. Thromb Haemost. 1998 May; 79(5):1063-4.
      View in: PubMed
    168. Stein JH, Rosenson RS. Treatment of severe hypertriglyceridemia lowers plasma viscosity. Atherosclerosis. 1998 Apr; 137(2):401-5.
      View in: PubMed
    169. Rosenson RS, Staffileno BA, Tangney CC. Effects of tourniquet technique, order of draw, and sample storage on plasma fibrinogen. Clin Chem. 1998 Mar; 44(3):688-90.
      View in: PubMed
    170. Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med. 1997 Jun 9; 157(11):1170-6.
      View in: PubMed
    171. Rosenson RS, Hafner JM. Rheological changes in hypertensive patients treated with ramipril. Clin Hemorheol Microcirc. 1997 Jan-Feb; 17(1):41-6.
      View in: PubMed
    172. Tangney CC, Hafner JM, McQuiston BD, Domas AJ, Rosenson RS. Postprandial changes in plasma and serum viscosity and plasma lipids and lipoproteins after an acute test meal. Am J Clin Nutr. 1997 Jan; 65(1):36-40.
      View in: PubMed
    173. Rosenson RS, Tangney CC. Beneficial effects of statins. Lancet. 1996 Dec 7; 348(9041):1583.
      View in: PubMed
    174. Rosenson RS, McCormick A, Uretz EF. Distribution of blood viscosity values and biochemical correlates in healthy adults. Clin Chem. 1996 Aug; 42(8 Pt 1):1189-95.
      View in: PubMed
    175. Rosenson RS. Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med. 1996 Jun 24; 156(12):1278-84.
      View in: PubMed
    176. Kennedy HL, Rosenson RS. Physician use of beta-adrenergic blocking therapy: a changing perspective. J Am Coll Cardiol. 1995 Aug; 26(2):547-52.
      View in: PubMed
    177. Stamos T, Rosenson RS. Cholesterol and coronary heart disease risk in elderly patients. JAMA. 1995 May 3; 273(17):1330; author reply 1330-1.
      View in: PubMed
    178. Rosenson RS, Tangney CC, Hafner JM. Intraindividual variability of fibrinogen levels and cardiovascular risk profile. Arterioscler Thromb. 1994 Dec; 14(12):1928-32.
      View in: PubMed
    179. Rosenson RS, Stein JH. Efficacy of low-density-lipoprotein lowering with statins. Lancet. 1994 Sep 3; 344(8923):683.
      View in: PubMed
    180. Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol. 1994 Sep 1; 74(5):499-500.
      View in: PubMed
    181. Rosenson RS, Frauenheim WA, Tangney CC. Dyslipidemias and the secondary prevention of coronary heart disease. Dis Mon. 1994 Aug; 40(8):369-464.
      View in: PubMed
    182. Rosenson RS, Goranson NL. Lovastatin-associated sleep and mood disturbances. Am J Med. 1993 Nov; 95(5):548-9.
      View in: PubMed
    183. Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol. 1993 Sep; 22(3):933-40.
      View in: PubMed
    184. Rosenson RS. Low levels of high-density lipoprotein cholesterol (hypoalphalipoproteinemia). An approach to management. Arch Intern Med. 1993 Jul 12; 153(13):1528-38.
      View in: PubMed
    185. Rosenson RS. Gemfibrozil-lovastatin-associated myalgia. Am J Cardiol. 1993 Feb 15; 71(5):497.
      View in: PubMed
    186. Rosenson RS. Cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1992 Feb 13; 326(7):491; author reply 491-2.
      View in: PubMed
    187. Rosenson RS, Baker AL, Chow MJ, Hay RV. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis. Gastroenterology. 1990 May; 98(5 Pt 1):1351-7.
      View in: PubMed
    188. Hay RV, Rosenson RS. Pathophysiology and management of hypercholesterolemia. Compr Ther. 1989 Apr; 15(4):45-53.
      View in: PubMed
    189. Rosenson RS, Sutton MS. Dissecting aneurysm of the pulmonary trunk in mitral stenosis. Am J Cardiol. 1986 Nov 15; 58(11):1140-1.
      View in: PubMed
    190. Rosenson RS, Mudge GH, Sutton MG. Nemaline cardiomyopathy. Am J Cardiol. 1986 Jul 1; 58(1):175-7.
      View in: PubMed
    191. Rosenson RS, Reinisch CL. Induction of T-cell proliferation by an Ia+ monocytic tumor clone. Cell Immunol. 1984 Mar; 84(1):41-50.
      View in: PubMed
    192. McNamara DB, Hussey JL, Kerstein MD, Rosenson RS, Hyman AL, Kadowitz PJ. Modulation of prostacyclin synthetase and unmasking of PGE2 isomerase in bovine coronary arterial microsomes. Biochem Biophys Res Commun. 1984 Jan 13; 118(1):33-9.
      View in: PubMed
    193. Michaelson J, Boyse EA, Chorney M, Flaherty L, Fleissner E, Hämmerling U, Reinisch C, Rosenson R, Shen FW. The biochemical genetics of the Qa-Tla region. Transplant Proc. 1983 Dec; 15(4):2033-8.
      View in: PubMed
    194. Kadowitz PJ, Nandiwada PA, Spannhake EW, Rosenson RS, McNamara DB, Hyman AL. Pulmonary vascular responses to thromboxane A2 as unmasked by OKY-1581. A novel inhibitor of thromboxane synthesis. Chest. 1983 May; 83(5 Suppl):72S-74S.
      View in: PubMed
    195. Michaelson J, Rosenson RS, Reinisch CL, Flaherty L. Biochemical isolation of Qa-2 molecules expressed on Qa-2+ leukemias arising in Qa-2- mice. Immunogenetics. 1983; 18(2):155-7.
      View in: PubMed
    196. Rao A, Allard WJ, Hogan PG, Rosenson RS, Cantor H. Alloreactive T-cell clones. Ly phenotypes predict both function and specificity for major histocompatibility complex products. Immunogenetics. 1983; 17(2):147-65.
      View in: PubMed
    197. Rosenson RS, Flaherty L, Levine H, Reinisch CL. Repeated isolation of unique Qa2+ Ia+ clonally derived cell lines from Qa2- mice. J Immunol. 1982 Jul; 129(1):382-7.
      View in: PubMed
    198. Rosenson RS, Flaherty L, Reinisch CL. Induction of surface Qa2 on lymphoid cells. J Immunol. 1981 Jun; 126(6):2253-7.
      View in: PubMed
    199. Brimijoin S, Olsen J, Rosenson R. Comparison of the temperature-dependence of rapid axonal transport and microtubules in nerves of the rabbit and bullfrog. J Physiol. 1979 Feb; 287:303-14.
      View in: PubMed
    Rosenson's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067